Phase 3 N=24 Treatment of Adrenal Insufficiency in Children
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 3 N=64 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Adrenal Insufficiency
Primary: Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A — 3962.0; 4879.6 hour*nanomole…
N/A N=30 Evaluation of Etomidate on Adrenal Function in Trauma Patients
Adrenal Insufficiency
Primary: Cortisol Levels Pre and Post Rapid Sequence Induction and Cortisol Stimulation Test
N/A N=22 Value of 25 mcg Cortrosyn Stimulation Test
Adrenal Insufficiency
Primary: Pearson Correlation of the Total Cortisol Levels Between the ITT and CSTs — 0.8; 0.86; 0.93; 0.92 correlation coefficient
Phase 2 N=8 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Phase 4 N=60 Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)
Adrenal Insufficiency
Primary: Change in Cognition After 10 Weeks of Treatment With a Low Dose of Hydrocortisone Compared to 10 Weeks of Treatment With a High Dose of Hydrocortisone. — -0.41; -0.42…
Phase 2 N=5 Dexamethasone Treatment of Congenital Adrenal Hyperplasia
Adrenal Hyperplasia, Congenital
Primary: Percent Difference in the Mean Log Transformed Area Under the Curve of 17-hydroxyprogesterone Between Regimens — 3.16; 3.91 Log Mean Area Under the Curve — p=0.09
Phase 1 N=11 Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · Hyperplasia · Adrenal Hyperplasia
Primary: Cortisol Exposure — 110 hr*mcg/dL
N/A N=7 Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
Adrenal Insufficiency
Primary: Number of Participants With Adrenal Insufficiency — 7 participants
Phase 3 N=31 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
Nephrotic Syndrome
Primary: Number of Participants Experienced a Relapse of Nephrotic Syndrome — 14; 15 Participants
Phase 2 N=14 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Phase 2 N=25 Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
Plaque Psoriasis
Primary: Hypothalamic-Pituitary-Adrenal (HPA) Axis Response — 19; 6 Participants
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
Phase 3 N=122 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Change From Baseline to 24 Weeks of the Mean of the 24-hour Standard Deviation Score (SDS) Profile for 17-OHP — -0.403; -0.172 Z-score — p==0.5521
Phase 2 N=28 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
Atopic Dermatitis
Primary: The Number of Patients in the Study With HPA Axis Suppression — 8; 9 Participants
Phase 2 N=24 Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
Psoriasis
Primary: Proportion of Patients in the Study With HPA Axis Suppression — 1; 13 Participants
Phase 2 N=16 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
Plaque Psoriasis
Primary: Proportion of Patients in the Study With HPA Axis Suppression — 1; 0; 10; 0 Participants
Phase 2 N=18 Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata
Alopecia Areata
Primary: Mean Change in Cortisol Levels From Baseline to Week 24 — 0.187 mg/dL
Phase 4 N=8 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
Phase 1 N=14 An Investigational Study of Hydrocortisone
Adrenal Insufficiency
Primary: Maximum Serum Concentration (Cmax) — 940.012; 896.489; 1563.479 nmol/L
Phase 3 N=55 Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Percentage of Participants Who Were Biochemical Responders at Week 28 — 40.0; 14.3 percentage of participants — p=0.0003
Phase 3 N=137 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Phase 3 N=18 Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
Adrenal Tumors
Primary: Increase in Catecholamine
Phase 2 N=35 Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's Syndrome
Primary: Percentage of Participants With One or More Adverse Events — 15; 18 Participants
Phase 2 N=16 Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH
Endocrine Disease · Adrenal Insufficiency · Congenital Adrenal Hyperplasia
Primary: Pharmacokinetic Profile (Cmax) Following Short-term Treatment With Chronocort® in Adult Patients With Congenital Adrenal Hyperplasia — 601.213 nmol/L
Phase 3 N=50 The Adrenal Contribution to Androgen Production in Girls During Puberty
Development
Primary: 17-hydroxyprogesterone Response to ACTH — 2.4; 3.7; 3.1; 2.9 ng/mL
Phase 4 N=15 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
Phase 1 N=10 Diagnosing Natriuretic Peptide Deficiency
Healthy · Lean
Primary: Changes in NT-proANP From Baseline to 8 Hours — -0.33 nmol/l
Phase 4 N=37 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Hyperglycemia · Diabetes Mellitus
Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35